Drug Details
| General Information of the Drug (ID: DR2875) | ||||
|---|---|---|---|---|
| Name |
Hydrocinchonine
|
|||
| Synonyms |
Hydrocinchonine; 485-65-4; Dihydrocinchonine; (1S)-((2R,4S,5R)-5-Ethylquinuclidin-2-yl)(quinolin-4-yl)methanol; UNII-ZPF9J31NM8; (+)-hydrocinchonine; TCMDC-125880; ZPF9J31NM8; (9S)-10,11-Dihydrocinchonan-9-ol; (S)-[(2R,4S,5R)-5-ethyl-1-azabicyclo[2.2.2]octan-2-yl]-quinolin-4-ylmethanol; EINECS 207-621-8; (+)-Dihydrocinchonine; SCHEMBL192607; CHEMBL548921; DTXSID30878431; CHEBI:174145; 6625AB; ZINC13826669; AC-30195; (+)-Dihydrocinchonine, analytical standard; Q27295839; Hydrocinchonine, >=95.0% (sum of enantiomers, HPLC); (S)-((2R,4S,5R)-5-ethylquinuclidin-2-yl)(quinolin-4-yl)methanol
Click to Show/Hide
|
|||
| Molecular Type |
Small molecule
|
|||
| Disease | Uterine Sarcoma [ICD-11: 2B5F] | Investigative | [1] | |
| Structure |
|
Click to Download Mol2D MOL |
||
| Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product | ||||
| Formula |
C19H24N2O
|
|||
| PubChem CID | ||||
| Canonical SMILES |
CCC1CN2CCC1CC2C(C3=CC=NC4=CC=CC=C34)O
|
|||
| InChI |
1S/C19H24N2O/c1-2-13-12-21-10-8-14(13)11-18(21)19(22)16-7-9-20-17-6-4-3-5-15(16)17/h3-7,9,13-14,18-19,22H,2,8,10-12H2,1H3/t13-,14-,18+,19-/m0/s1
|
|||
| InChIKey |
WFJNHVWTKZUUTR-QAMTZSDWSA-N
|
|||
| CAS Number |
CAS 485-65-4
|
|||
| ChEBI ID | ||||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. A List of Natural Product(s) Able to Reverse the Resistance of This Drug | ||||||
| Cinchonine | Cinchona calisaya | Click to Show/Hide the Molecular Data of This NP | ||||
| Reversing Drug Resistance | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [1] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Down-regulation | Expression | ABCB1 | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Cleavage | CASP3 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Cleavage | PARP1 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | MES-SA | CVCL_1404 | Uterine corpus sarcoma | Homo sapiens | ||
| MES-SA/Dx5 | CVCL_2598 | Uterine corpus sarcoma | Homo sapiens | |||
| Experimental
Result(s) |
Hydrocinchonine exerted MDR reversal activity and synergistic apoptotic effect with TAX in MES-SA/DX5 cells almost comparable with quinidine and cinchonine as a potent MDR-reversal and combined therapy agent with TAX. | |||||
